How Patient-Reported Bother by Side Effects Predicts Cancer Treatment Discontinuation

Learn how a single patient-reported question—FACT-GP5, which asks how bothersome treatment side effects have been over the past week—can help predict early discontinuation of cancer therapy. This video from the ECOG-ACRIN Cancer Research Group shares clinical trial findings showing that patients who report greater side effect bother at the start of treatment are more likely to stop therapy early. The GP5 item offers a simple yet powerful tool to help clinicians and researchers identify patients at risk and improve care. Funded by the National Cancer Institute (NCI), this work was developed by a team at UNC Lineberger Comprehensive Cancer Center, Northwestern University, the Wake Forest School of Medicine, and the ECOG-ACRIN Statistical Centers at Dana-Farber Cancer Institute and Brown University. It is part of the NCI Cancer Moonshot Treatment Tolerability Consortium—a nationwide effort to improve how patient-reported outcomes are measured and used in cancer trials. Visit the NCI Treatment Tolerability Consortium website to learn more about its groundbreaking work to enhance cancer care by improving patient-reported outcomes and treatment tolerability for all patients.